21 research outputs found
Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children
This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor
processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy.
Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a
crossover study of risperidone and placebo for 2 weeks each. Dependent measures included tests of sustained
attention, memory, visual matching, tremor, seat activity, abnormal movements, and parent behavior ratings.
Results were compared by repeated measures ANOVA Fourteen boys and 2 girls with disruptive behavior
and IQ ≤ 84 all completed the protocol. Risperidone was superior to placebo on response time (p = 0.01, ηP ^
2 =
0.43) and seat movement (p < 0.05, ηP ^
2 = 0.29) on a short-term memory task, and on a measure of static tremor
(p = 0.05, ηP ^
2 = 0.28). There was not a significant difference between treatment conditions on the Abnormal
Involuntary Movement scale. Risperidone was superior to placebo on three subscales of the Nisonger Child
Behavior Rating Form [Overly Sensitive (p < 0.01, ηP ^
2 = 0.44), Conduct Problem (p = 0.02, ηP ^
2 = 0.36),
Hyperactivity (p = 0.03, ηP ^
2 = 0.32)] and on the Hyperactivity/Noncompliance subscale of the Aberrant
Behavior Checklist (p = 0.01, ηP ^
2 = 0.41). Significant increases in heart rate (p = 0.05, ηP ^
2 = 0.27) and weight (p
= 0.02, ηP ^
2 = 0.36) occurred in the risperidone condition. The findings suggest a beneficial effect of
risperidone after several months of treatment on efficiency of responding, activity level, static tremor, and
aspects of behavior
Serum Zinc Correlates with Parent- and Teacher-Rated Inattention in Children with Attention-Deficit/Hyperactivity Disorder
Objective:
The aim of this study was to explore the relationship of zinc nutrition to the severity of attentiondeficit/
hyperactivity disorder (ADHD) symptoms in a middle-class American sample with well-diagnosed
ADHD. Previous reports of zinc in ADHD, including two positive clinical trials of supplementation, have
come mainly from countries and cultures with different diets and/or socioeconomic realities. Method:
Children 5–10 years of age with DISC- and clinician-diagnosed ADHD had serum zinc determinations and
parent and teacher ratings of ADHD symptoms. Zinc levels were correlated (Pearson’s and multiple
regression) with ADHD symptom ratings. Results: Forty-eight children (37 boys, 11 girls; 33 combined
type, 15 inattentive) had serum zinc levels with a median/mode at the lowest 30% of the laboratory
reference range; 44 children also had parent/teacher ratings. Serum magnesium levels were normal.
Nutritional intake by a parent-answered food frequency questionnaire was unremarkable. Serum zinc
correlated at r = -0.45 (p = 0.004) with parent-teacher-rated inattention, even after controlling for gender,
age, income, and diagnostic subtype, but only at r = -0.20 (p = 0.22) with CPT omission errors. In contrast,
correlation with parent-teacher-rated hyperactivity-impulsivity was nonsignificant in the opposite direction.
Conclusion: These findings add to accumulating evidence for a possible role of zinc in ADHD, even for
middle-class Americans, and, for the first time, suggest a special relationship to inattentive symptoms.
They do not establish either that zinc deficiency causes ADHD nor that ADHD should be treated with zinc.
Hypothesis-testing clinical trials are needed
Vestibular Stimulation for ADHD: Randomized Controlled Trial of Comprehensive Motion Apparatus
Objective:
This research evaluates effects of vestibular stimulation by Comprehensive Motion Apparatus
(CMA) in ADHD.
Method:
Children ages 6 to 12 (48 boys, 5 girls) with ADHD were randomized to thrice-weekly 30-min
treatments for 12 weeks with CMA, stimulating otoliths and semicircular canals, or a single-blind control of
equal duration and intensity, each treatment followed by a 20-min typing tutorial.
Results:
In intent-to-treat analysis (n = 50), primary outcome improved significantly in both groups (p =
.0001, d = 1.09 to 1.30), but treatment difference not significant (p = .7). Control children regressed by
follow-up (difference p = .034, d = 0.65), but overall difference was not significant (p = .13, d = .47). No
measure showed significant treatment differences at treatment end, but one did at follow-up. Children with
IQ-achievement discrepancy ≥ 1 SD showed significantly more CMA advantage on three measures.
Conclusion:
This study illustrates the importance of a credible control condition of equal duration and intensity
in trials of novel treatments. CMA treatment cannot be recommended for combined-type ADHD without
learning disorder
Recommended from our members
Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use
Abstract Objectives: Studies in humans and rodents suggest that metformin, a medicine typically used to treat type 2 diabetes, may have beneficial effects on memory. We sought to determine whether metformin improved spatial or verbal memory in children with autism spectrum disorder (ASD) and overweight associated with atypical antipsychotic use. Methods: We studied the effects of metformin (Riomet®) concentrate on spatial and verbal memory in 51 youth with ASD, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management. Phase 1 was a 16-week, randomized, double-blind, placebo-controlled, parallel-group comparison of metformin (500–850 mg given twice a day) versus placebo. During Phase 2, all participants took open-label metformin from week 17 through week 32. We assessed spatial and verbal memory using the Neuropsychological Assessment 2nd Edition (NEPSY–II) and a modified children's verbal learning task. Results: No measures differed between participants randomized to metformin versus placebo, at either 16 or 32 weeks, after adjustment for multiple comparisons. Sixteen-week change in memory for spatial location on the NEPSY–II was nominally better among participants randomized to placebo. However, patterns of treatment response across all measures revealed no systematic differences in performance, suggesting that metformin had no effect on spatial or verbal memory in these children. Conclusions: Although further study is needed to support these null effects, the overall impression is that metformin does not affect memory in overweight youth with ASD who were taking atypical antipsychotic medications
Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Objective:
The objective of this research was to explore the effects of risperidone on cognitive processes in
children with autism and irritable behavior.
Method:
Thirty-eight children, ages 5-17 years with autism and severe behavioral disturbance, were
randomly assigned to risperidone (0.5 to 3.5 mg/day) or placebo for 8 weeks. This sample of 38 was a subset
of 101 subjects who participated in the clinical trial; 63 were unable to perform the cognitive tasks. A
double-blind placebo-controlled parallel groups design was used. Dependent measures included tests of
sustained attention, verbal learning, hand-eye coordination, and spatial memory assessed before, during, and
after the 8-week treatment. Changes in performance were compared by repeated measures ANOVA.
Results:
Twenty-nine boys and 9 girls with autism and severe behavioral disturbance and a mental age ≥18
months completed the cognitive part of the study. No decline in performance occurred with risperidone.
Performance on a cancellation task (number of correct detections) and a verbal learning task (word
recognition) was better on risperidone than on placebo (without correction for multiplicity). Equivocal
improvement also occurred on a spatial memory task. There were no significant differences between
treatment conditions on the Purdue Pegboard (hand-eye coordination) task or the Analog Classroom Task
(timed math test).
Conclusion:
Risperidone given to children with autism at doses up to 3.5 mg for up to 8 weeks appears to have no
detrimental effect on cognitive performance
Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial
OBJECTIVE:
Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1-2 year follow-up period.
METHODS:
In a naturalistic study, 84 children and adolescents 5-17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy.
RESULTS:
Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow-up. Several other measures of maladaptive behavior (some related to socialization) also showed improved functioning in association with risperidone on the ABC or on the Modified Real Life Rating Scale.
CONCLUSIONS:
Increased appetite, weight gain, and enuresis are risks associated with long-term risperidone. Our data suggest that these risks were balanced by longer-term behavioral and social benefits for many children over 1.8 years of ongoing treatment